INSPIRE - S
Stroke registry

Contact a representative

The Medtronic commitment to delivering high-quality data.

INSPIRE-S reflects this commitment, supported by real-world data, core lab and CEC adjudication and the registry is endorsed by ESMINT. It evaluates three first-line techniques for endovascular thrombectomy.

Download the synopsis

Stent retriever only

Solitaire™ X revascularization device and Solitaire™ Platinum revascularization device^†

Aspiration only

React™ 68/71 catheters

Solitaire X product illustration with grey background circle

Combination therapy

Solitaire™ revascularization device† and React™ 68/71 catheters (or market-approved aspiration catheter)

Excellent real-world safety and efficacy outcomes

The Solitaire™ revascularization device^† and React™ catheter deliver excellent real-world outcomes, with consistent results and a strong safety record.

55.1%

mRS 0-2
at 90 days

73.5%

Final successful revascularization*
eTICI ≥2c

46.5%

First pass **
eTICI ≥2c

1.5%

Symptomatic intracranial hemorrhage
24 hours

Our results are supported by core lab and CEC adjudication, and the registry has received endorsement from ESMINT.

802 patients
29 sites - 13 countries

Inspire- S map left side: Europe, Africa, Americas

Inspire- S map right side: Asia, Oceania

Outcome by cohort

Outcome	All n=802	Combination therapy n=397	Stent retriever only n=259	Aspiration only n=146
mRS 0-2 or return to pre-stroke mRS at 90 days	57.1%	56.6%	60.5%	52.8%
mRS 0-2 at 90 days	55.1%	53.9%	58.9%	51.4%
First pass revascularization^‡
eTICI ≥2b50	61.6%	60.4%	64.6%	54.9%
eTICI ≥2c	46.5%	47.5%	48.6%	39.9%
Final revascularization^‡
eTICI ≥2b50	11.8%	23.9%	0.0%	0.0%
eTICI ≥2c	73.5%	72.0%	77.4%	70.6%
sICH (24 hours)^§¶	1.5%	1.5%	1.5%	1.4%

Good clinical outcomes

Acute ischemic stroke main clinical effectiveness outcomes

Death is imputed to 6. A total of 770 patients (380 for Combination, 248 for Stent Retriever-only, 142 for Aspiration-only) had mRS data at 90 days.

Fill in the form if you would like to be contacted by one of representatives with more information regarding INSPIRE-S and AIS products

*Indicates Required Field

Please select at least one option below:*

I would like to be contacted by a Medtronic representative

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content. For more information, see the Medtronic privacy notice.

You can always change your preferences or update your personal details by visiting the Preference center.

See the Preference center

Limitations: This data is being presented in advance of publication in a peer-reviewed journal, so its review is limited to the steering committee and registry sponsor. Data is subject to change upon final publication.

^{* Final revascularization eTICI≥2c 585/796 patients.}

^{** First pass eTICI≥2c 370/796 patients}

^{† Includes Solitaire™ X revascularization device, primarily, with Solitaire™ Platinum revascularization device.}

^{‡ A total of 796 patients had core lab data available. Sample size is 796 for all, 396 for combination therapy, 257 for stent retriever only, and 143 for aspiration only.}

^{§ CEC-adjudicated.}

^{¶ sICH: Defined as any intracranial hemorrhage with an increase of 4 points or more in the NIHSS score within the 24 hours post-procedure visit window, or that led to death and that was identified as the predominant cause of the neurologic deterioration.}

Data on file; 2024 09 19 NTF_INSPIRE S EMEA Primary Results Data Release.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals.

See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic’s website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser.

For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative and/or consult Medtronic’s websites.

INSPIRE - S Stroke registry